Abstract:
:The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all opioids; however, its pharmacokinetic characteristics are unique. Favourable pharmacokinetic properties, minimally altered by extremes of age or renal or hepatic dysfunction, enable easy titration and rapid dissipation of clinical effect of this agent, even after prolonged infusion. Remifentanil is metabolised by esterases that are widespread throughout the plasma, red blood cells, and interstitial tissues, whereas other anilidopiperidine opioids (e.g. fentanyl, alfentanil and sufentanil) depend upon hepatic biotransformation and renal excretion for elimination. Consequently, remifentanil is cleared considerably more rapidly than other anilidopiperidine opioids. In addition, its pKa (the pH at which the drug is 50% ionised) is less than physiological pH; thus, remifentanil circulates primarily in the non-ionised moiety, which quickly penetrates the lipid blood-brain barrier and rapidly equilibrates across the plasma/effect site interface. By virtue of these distinctive pharmacokinetic properties, the context-sensitive half-time (i.e. the time required for the drug's plasma concentration to decrease by 50% after cessation of an infusion) of remifentanil remains consistently short (3.2 minutes), even following an infusion of long duration (> or =8 hours). Remifentanil, a clinically versatile opioid, is useful for intravenous analgesia and sedation in spontaneously breathing patients undergoing painful procedures. Profound analgesia may be achieved with minimal effect on cognitive function. Remifentanil may also provide sedation and analgesia during placement of regional anaesthetic blocks, and in conjunction with topical anaesthesia and airway nerve blocks, it may be useful for blunting reflex responses and facilitating 'awake' fibreoptic intubation. Compared with fentanyl and alfentanil in a day-surgery setting, remifentanil supplementation of general anaesthesia may improve intraoperative haemodynamic control. Both emergence time and the incidence of respiratory depression during post-anaesthetic recovery may be reduced. However, outcomes such as home discharge time, post-emergence adverse effect profile, and patient and provider satisfaction are not significantly improved, and the incidence of intraoperative hypotension and bradycardia is greater. In addition, drug acquisition costs for remifentanil are higher and clinicians may need extra time to familiarise themselves with the drug's unique pharmacokinetics.Ironically, the quick dissipation of opioid analgesic effect following remifentanil discontinuation may be a significant clinical disadvantage. Unless little or no postoperative pain is anticipated, the clinician may wish to treat prospectively using local or regional anaesthesia, non-opioid analgesics, or longer-acting opioid analgesics.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Beers R,Camporesi Edoi
10.2165/00023210-200418150-00004subject
Has Abstractpub_date
2004-01-01 00:00:00pages
1085-104issue
15eissn
1172-7047issn
1179-1934pii
18154journal_volume
18pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract::Clinically relevant movement disorders are identified in 3% of patients with HIV infection seen at tertiary referral centres. In the same setting, prospective follow-up shows that 50% of patients with AIDS develop tremor, parkinsonism or other extrapyramidal features. Hemiballism-hemichorea and tremor are the most com...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200216100-00002
更新日期:2002-01-01 00:00:00
abstract::There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-020-00727-3
更新日期:2020-06-01 00:00:00
abstract::Oxcarbazepine (Trileptal, Timox) is structurally related to carbamazepine and has anticonvulsant activity. Studies suggest that the anticonvulsant activity of oxcarbazepine is mediated via the blocking of neuronal ion channels. In patients aged <18 years, the efficacy of oxcarbazepine monotherapy was similar to that o...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-200418010-00006
更新日期:2004-01-01 00:00:00
abstract:BACKGROUND:When otherwise unexplained, syncope in patients with Alzheimer's disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer's disease. METHODS:Conse...
journal_title:CNS drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00023210-200620050-00005
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-020-00700-0
更新日期:2020-02-01 00:00:00
abstract:BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-017-0421-4
更新日期:2017-04-01 00:00:00
abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11208340-000000000-00000
更新日期:2011-10-01 00:00:00
abstract::Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-199809040-00003
更新日期:1998-04-01 00:00:00
abstract::Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200822060-00002
更新日期:2008-01-01 00:00:00
abstract:UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115030-00006
更新日期:2001-01-01 00:00:00
abstract:BACKGROUND:Few studies examine predictors of seizures in medically treated patients with epilepsy receiving antiepileptic monotherapy using a large patient population. OBJECTIVE:Our objective was to identify clinical, medication, and demographic factors associated with seizure recurrence in medically treated patients ...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-014-0191-1
更新日期:2014-11-01 00:00:00
abstract::Disability, characterised by the loss of ability to perform activities of daily living (ADL), is a defining feature of dementia that results in growing caregiver burden and the eventual need for alternative care or nursing home placement. Functional decline in patients with dementia can also result from causes other t...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418130-00003
更新日期:2004-01-01 00:00:00
abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-019-00641-3
更新日期:2019-08-01 00:00:00
abstract::Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11202620-000000000-00000
更新日期:2010-01-01 00:00:00
abstract::Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11587860-000000000-00000
更新日期:2011-07-01 00:00:00
abstract::Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing-remitting (RR) phase. Our incomplete understanding of the pathological mechanisms u...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-016-0340-9
更新日期:2016-06-01 00:00:00
abstract::Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11530280-000000000-00000
更新日期:2010-02-01 00:00:00
abstract::Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in hormonal responses, brain ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11310990-000000000-00000
更新日期:2009-12-01 00:00:00
abstract:BACKGROUND:The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated considerable optimism that better antipsychotic treatments for schizophrenia and bipolar disorder were possible. SGAs offer several tolerability benefits over first-generation antipsychotics (FGAs), particularly wit...
journal_title:CNS drugs
pub_type: 杂志文章,meta分析,评审
doi:10.2165/11634500-000000000-00000
更新日期:2012-09-01 00:00:00
abstract:INTRODUCTION:The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. OBJECTIV...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-016-0359-y
更新日期:2016-07-01 00:00:00
abstract:INTRODUCTION:The use of methylphenidate for the treatment of attention deficit-hyperactivity disorder (ADHD) has increased dramatically in the past decade in some countries in Europe and North America. In response to a public debate in Israel, several Knesset members introduced a legislative initiative that aims to lim...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-200317120-00005
更新日期:2003-01-01 00:00:00
abstract::Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-016-0337-4
更新日期:2016-05-01 00:00:00
abstract::Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomi...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-018-0511-y
更新日期:2018-04-01 00:00:00
abstract::Sodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic-clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic dr...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-017-0441-0
更新日期:2017-07-01 00:00:00
abstract::Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200317070-00004
更新日期:2003-01-01 00:00:00
abstract::Schizophrenia is a long-term psychiatric disorder that impacts important mental functions and requires indefinite treatment, as well as psychosocial and economic support. The introduction of chlorpromazine, the first antipsychotic, and the subsequent development of a long list of similar dopamine-blocking antipsychoti...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-018-0588-3
更新日期:2019-01-01 00:00:00
abstract::The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00756-y
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND AND OBJECTIVE:Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-level data were used t...
journal_title:CNS drugs
pub_type: 杂志文章,随机对照试验
doi:10.1007/s40263-017-0462-8
更新日期:2017-10-01 00:00:00
abstract::The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115110-00004
更新日期:2001-01-01 00:00:00
abstract:BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00708-6
更新日期:2020-03-01 00:00:00